Ronald Kosanke
Medical · Ganado, TXNPI 1033301866
Payments from drug & device makers
Across 147 payments — averaging $16.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Bayer$292
- Lilly USA, LLC$235
- Novo Nordisk$144
- Boehringer Ingelheim$120
- Biohaven Pharmaceutical Holding Company Ltd.$67
- plus $441 from 15 others
What the payments were for
- Food & beverage$2,33799%
- Education$171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 66 | $1,054 |
| Bayer | 18 | $292 |
| Lilly USA, LLC | 19 | $235 |
| Novo Nordisk | 8 | $144 |
| Boehringer Ingelheim | 7 | $120 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $67 |
| Genentech USA, Inc. | 5 | $65 |
| AstraZeneca | 3 | $52 |
| Merck | 3 | $39 |
| Mylan Specialty L.p. | 1 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Amgen | 1 | $32 |
| Viatris Specialty LLC | 2 | $28 |
| Biohaven Pharmaceuticals, Inc. | 1 | $25 |
| GSK | 1 | $25 |
| Eisai Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Pfizer | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Shield Therapeutics Inc | 1 | $14 |
How this compares
$2,354 in reported general payments places this provider in the 70th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 28 | $28,317 |
| EliquisApixaban | 28 | $27,761 |
| MounjaroTirzepatide | 12 | $14,542 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $11,466 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,483 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $6,900 |
| Diclofenac Sodium | 84 | $1,933 |
| Alprazolam | 179 | $1,180 |
| Atorvastatin Calcium | 125 | $1,085 |
| Gabapentin | 71 | $847 |
| Metoprolol Succinate | 57 | $846 |
| Pioglitazone Hcl | 51 | $825 |
| Sertraline Hcl | 79 | $804 |
| Levothyroxine Sodium | 100 | $785 |
| Lisinopril | 111 | $784 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $144 | $28,31728 claims |
| PfizerEliquis | $18 | $27,76128 claims |
| MerckJanumet Xr, Janumet | $39 | $18,36634 claims |
| Lilly USA, LLCMounjaro | $235 | $14,54212 claims |
| GSKTrelegy Ellipta | $25 | $7,48312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,490 medical providers in Texas.
Other medical in Ganado
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Courtney AldridgeSan Antonio$129K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
- Janine ShinnDallas$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.